Clinical diagnostic company Renalytix AI has expanded its partnership with the Joslin Diabetes Center to integrate new biomarkers for kidney disease discovered by the center's researchers into the company’s KidneyIntelX platform.
KidneyIntelX is an in vitro diagnostic platform that assesses the risk of adverse kidney outcomes in patients with Type 2 diabetes and early-stage kidney disease. By...
Medical imaging company Nanox and USARD Holdings, a teleradiology service provider, have expanded their strategic collaboration agreement to offer radiology diagnostic services to healthcare stakeholders, including insurance companies, outpatient imaging centers and others.
“This collaboration between Nanox and USARAD on advanced diagnostics has the potential to transform the quality of...
Artificial intelligence-enabled in vitro diagnostics company Renalytix AI announced today a research partnership with AstraZeneca to develop and launch medical strategies for cardiovascular, renal and metabolic diseases.
The first stage of the collaboration will use KidneyIntelX, an AI-enabled in vitro diagnostic platform that gathers patient data from electronic medical records to generate a...
Decentralized digital therapeutic trial. Pear Therapeutics has enrolled the first participant in the DREAM study, an open-label trial of its Somryst prescription digital therapeutic for chronic insomnia.
Conducted as a decentralized trial, the effort will recruit U.S. adults aged 22 to 75 years who have an Insomnia Severity Index score of 8 or higher, as well as at least three months of insomnia...
